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An Unmet Need in Heart Failure
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Heart failure (HF) is a common, disabling, and costly disease. Despite major advances in medical therapy, morbidity
and mortality remain high, in part because current pharmacological regimens may not fully address some unique
requirements of the heart for energy. The heart requires a continuous supply of energy-providing substrates and
amino acids in order to maintain its function. In HF, defects in substrate metabolism and cardiac energy and sub-
strate utilization may contribute to contractile dysfunction. HF is often accompanied by a deficiency in key micronutri-
ents required for unimpeded energy transfer. Correcting these deficits has been proposed as a method to limit or
even reverse the progressive myocyte dysfunction and/or necrosis in HF. This review summarizes the existing HF liter-
ature with respect to supplementation trials of key micronutrients involved in cardiac metabolism: coenzyme Q10,
L-carnitine, thiamine, and amino acids, including taurine. Studies using a broader approach to supplementation are
also considered. Although some of the results are promising, none are conclusive. There is a need for a prospective
trial to examine the effects of micronutrient supplementation on morbidity and mortality in patients with HF. (J Am
Coll Cardiol 2009;54:1660–73) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.012t
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aeart failure (HF) is a common, disabling, and costly
isease throughout the world (1,2). Annual costs related to
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ccepted August 25, 2009.he treatment of HF in the U.S. are estimated at $38 billion,
nd account for 5.4% of the health care budget (3). The
reatment of HF is based on medical guidelines published
y the professional societies (4–7). The recommended
harmacological therapy includes the use of angiotensin-
onverting enzyme inhibitors, angiotensin receptor blockers,
iuretics, beta-blockers, and aldosterone antagonists.
dditional nonpharmacologic measures, such as cardiac
esynchronization therapy, implantable cardioverter-
efibrillators, and exercise training, have shown beneficial
utcomes in quality of life, morbidity, and/or mortality of
F patients (7).
Despite improvements in mortality, HF hospitaliza-
ions continue to rise (8). Hospitalization for HF is a
trong predictor of poor prognosis and is associated with
ost-discharge mortality and readmission rates that can
e as high as 15% and 30%, respectively, within 60 to 90
ays (9,10). Although new therapeutic options have un-
oubtedly improved morbidity and mortality, additional
nterventions are needed to prevent progression of HF and
mprove outcomes (10,11).
Although current therapies have addressed hemodynam-
cs, neurohormonal modulation, and electrophysiological
spects of HF, these therapies have not targeted the meta-
olic needs of the failing heart (12).
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October 27, 2009:1660–73 Micronutrient Deficiencies: An Unmet Need in HFormal Cardiac Metabolism
he adult human heart, which weighs between 200 and
25 g, is a highly efficient converter of chemical energy to
echanical energy (13). This relatively small mass uses
ore energy, in the form of adenosine triphosphate (ATP),
han any other organ as it pumps 5 l of blood per minute,
,200 l per day, and over 2.6 million liters per year (14). It
s estimated that over 6 kg of ATP is hydrolyzed by the
eart daily for this pumping function (15). To maintain this
ssential level of efficiency, the enzymes, membranes, and
tructural elements of the heart undergo constant turnover
nd rebuilding. Every 30 days, an entire heart is recon-
tructed with brand-new protein components, using a
teady supply of nutritional building blocks in the form of
mino acids, lipids, and carbohydrates (16,17).
Energy transfer in the beating heart can be visualized as
system of interconnected cycles that receives nutrients
hrough the circulation and that transfers energy from
utrients to ATP, which, in turn, is used to support cyclic
ontractions (Fig. 1). Under normal conditions, the system
eadily responds to environmental changes by either increas-
ng or decreasing the rate of energy turnover. The schematic
efers to yet another biological principle: cycles consist of
oieties (e.g., blood in the circulation, enzymes in cells)
hat provide the necessary machinery for energy transfer.
The heart has also been described as a metabolic omni-
ore, because it has the capacity to oxidize fat and carbo-
ydrates simultaneously or interchangeably for its energy
eeds (18,19). Macronutrients are defined here as fats and
arbohydrates that constitute the main sources of ATP for
ontraction of the mammalian heart. Micronutrients, such as
oenzyme Q10 (CoQ10), L-carnitine, thiamine, amino
cids, including taurine, and other small molecules are
Macronutrients
Systemic 
Circulation 
(O2)
Cellular 
Metabolism
(ATP)
Crossbridges  
(Ca2+)
Contraction
Micronutrients
Figure 1 Cycles of Energy Transfer
and the Place of Micronutrients
Energy transfer in the heart as a system of interconnected cycles. Micronutri-
ents are essential components of moiety-conserved cycles in the cell. See the
Normal Cardiac Metabolism section for further discussion.oefined as essential cofactors for
nergy transfer, biochemical main-
enance, and physiological heart
unction (20,21).
etabolism in HF
eficiencies in CoQ10, L-carnitine,
hiamine and other B vitamins,
nd taurine are all well docu-
ented in the failing myocardium
22,23). Deficiencies of L-carnitine,
hiamine, and taurine alone are well-
stablished causes of cardiomyop-
thy (23). Animal models have
imilarly revealed that micronutri-
nt deficiencies are present in HF,
hat genetically induced deficien-
ies lead to HF, and that correc-
ion of these deficits can improve heart function (24–30).
hus, in HF, it has been proposed that the human heart is
eficient in adequate amounts of key nutrient cofactors or
icronutrients (Fig. 1) (23,31–36). However, the heart is “not
ut of fuel” as it has been suggested (34), because the coronary
irculation provides substrates in excess of their rate of utiliza-
ion. Indeed, a large part of the morbidity of HF appears to be
he result of impaired energy substrate metabolism (37). ATP
urnover in the failing myocardium may be reduced by as much
s 30%, although it is not clear whether the reduced rate of
TP turnover is the cause or the consequence of HF (38).
When the heart is stressed, as seen in HF, it returns to
he fetal gene program, switching from the dominant fatty
cid metabolism to a more efficient use of carbohydrates in
n attempt to limit further damage (39–44). It is also of
nterest that infants have a reduced ability to biosynthesize
-carnitine and taurine. Hence, these nutrients are man-
ated for inclusion in infant formulas. Whether the fetal
ene program contributes to the deficiencies of L-carnitine
nd taurine seen in HF is unknown. In any case, the early
daptation of the heart eventually becomes maladaptive as
F progresses (17,45). The evolution of HF usually occurs
ver a number of years; therefore, only a very small percent-
ge of cardiomyocytes at a given time may be irreversibly
njured. These myocytes retain a relatively preserved struc-
ure and are in a “vegetative state” equal to viable, but
ysfunctional, myocardium as a result of metabolic imbal-
nce, in part related to excessive and continuous activation
f the neuroendocrine system (31,32,46,47). Therapy with
icronutrients when deficiencies exist has the potential to
revent myocyte death and restore function.
In HF, maladaptive changes appear to occur at all steps of
nergy production and transfer: substrate utilization, oxida-
ive phosphorylation, and ATP utilization (37). Inadequate
nergy conversion in already overworked cardiomyocytes
ay potentially result in cell damage or death mediated by
Abbreviations
and Acronyms
ATP  adenosine
triphosphate
CoQ10  coenzyme Q10
EF  ejection fraction
HF  heart failure
LV  left ventricle/
ventricular
LVEDV  left ventricular
end-diastolic volume
LVESV  left ventricular
end-systolic volume
MRI  magnetic resonance
imaging
NYHA  New York Heart
Associationxidative stress, resulting in mitochondrial damage and
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Micronutrient Deficiencies: An Unmet Need in HF October 27, 2009:1660–73ytochrome c release (23,48). Decreased capacity for energy
onversion makes the damaged heart more susceptible to
schemia, accelerating the process of HF. In Figure 1, it is
roposed that micronutrients allow for the efficient and
ppropriate utilization of fuel for the preservation of normal
tructure and function of the heart. It should also be
ecognized that plasma levels of compounds such as
-carnitine, taurine, and CoQ10 may not reflect tissue levels
ecause of large transmembrane cellular gradients (23,49–53).
The lack of sufficient micronutrients may be intensified
y medical interventions. Commonly prescribed medica-
ions, such as the cholesterol-lowering HMG-CoA reduc-
ase inhibitors, have been shown to cause reductions in
erum CoQ10 levels, thus potentially exacerbating already-
resent nutritional deficiencies and limiting long-term
reatment success (54–59). Similarly, loop diuretics have
een shown to substantially lower thiamine levels in patients
ith HF (60–63).
icronutrient Supplementation
icronutrients may work synergistically with standard ther-
pies in patients with HF by correcting defects in energy
etabolism and providing the failing heart with deficient
ofactors that are limiting cellular energy transfer (Fig. 1).
espite the appeal of such a strategy, large clinical trials
valuating therapy with micronutrients are lacking (Table 1).
owever, this is a potentially promising new paradigm for
he treatment of HF therapy, deserving further investiga-
ion. Micronutrient supplementation offers the opportunity
o correct deficiencies in critical myocyte pathways, includ-
ng those associated with the provision of ATP (CoQ10,
-carnitine, thiamine and the B vitamins, amino acids),
rotein production (amino acids), intracellular calcium bal-
nce (taurine), and the reduction of oxidative stress (CoQ10
nd taurine).
To date, clinical research of a single micronutrient in the
reatment of HF has been the usual investigative approach.
owever, this method may potentially shift the rate-
imiting step to another pathway of the energy cascade.
here are only a few studies evaluating a broader, multiple-
icronutrient approach. Such an approach may be a more
omprehensive method of supplementation and overcome
ome of the limitations with a single-supplement method.
uideline Recommendations for Nutritional Support in HFTable 1 Guideline Recommendations for Nutritional Support in
Guideline Recommenda
ACC/AHA (7) Routine use of nutritional supplements of unproved v
HFSA (5) Patients with HF, especially those on diuretic therapy
for daily multivitamin-mineral supplementation to e
recommended daily value of essential nutrients
ESC (4) Omitted in 2008 guidelines
CCS (6) CoQ10, vitamin and herbal supplements are not reco
CC  American College of Cardiology; AHA  American Heart Association; CCS  Canadian Card
FSA  Heart Failure Society of America; N/A  not available.s described below, nutritional studies to date as a whole tave significant design drawbacks, indicating an important
eed for larger, more comprehensive micronutrient trials in
F.
he Need for More Clinical Trials
he subsequent sections will summarize the existing data in
his supplementation field, identify the limitations of cur-
ent studies, and propose how to move forward with
esearch to fill critical gaps in knowledge. Here, the focus is
rimarily on CoQ10, L-carnitine, thiamine, and taurine.
hese nutrients were chosen because: 1) they are known
ssential components for metabolic pathways that partici-
ate in energy production, myocardial calcium balance, and
xidative defenses; 2) there is evidence for a reduction in the
evel of each in HF; 3) there is evidence that a deficiency in
ach of them, alone, may result in cardiac or skeletal muscle
athology; and 4) there is possibly pathological reversal
27,64,65).
oQ10
oQ10, or ubiquinone, is an obligatory component of the
espiratory chain in mitochondria. It serves as a carrier for
lectrons flowing through complexes I, II, and III. As such,
oQ10 plays an essential role in ATP formation in most
issues, including the heart, skeletal muscle, brain, kidney,
nd liver. CoQ10 is localized in the inner mitochondrial
and other intracellular) membrane, where it serves to
tabilize these structures, control electron flow, and regulate
he flow of reducing equivalents (66,67). In addition to its
ole in energy transfer, CoQ10 also functions as an antiox-
dant and protects circulating low-density lipoprotein par-
icles from oxidation (68). Its inhibition of the mitochon-
rial permeability transition pore prevents the activation of
poptotic cascades and the oxidative inactivation of key
roteins involved in ATP production (69,70). The diverse
oles of CoQ10 in energy metabolism are important in the
ailing heart, where oxidation of energy-providing substrates
ecomes inadequate (54). Deficiency of CoQ10 can be
aused by inhibition of its synthesis. Mevalonate, a precur-
or of CoQ10, is formed in a pathway dependent on
MG-CoA reductase. Not surprisingly, statins, which
nhibit HMG-CoA reductase, have been shown to reduce
Level of Evidence
nd not recommended Class III, Level of Evidence: C
stricted diets, should be considered
adequate intake of the
Level of Evidence: C
N/A
ded as HF therapy Class III, Level of Evidence: C
lar Society; CoQ10  coenzyme Q10; ESC  European Society of Cardiology; HF  heart failure;HF
tion
alue a
and re
nsure
mmenhe production of CoQ10 (54–58).
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October 27, 2009:1660–73 Micronutrient Deficiencies: An Unmet Need in HFCoQ10 is widely available in dietary sources such as meat,
oultry, and oils, which together provide an average daily
ntake of 5 mg (71). However, the majority of CoQ10 is
roduced by the human body from tyrosine and mevalonate
hrough endogenous pathways. Trials involving CoQ10
upplementation in HF have primarily used dosage ranges
rom 60 to 300 mg/day. No significant toxicity has been
bserved in human studies, although there have been
dverse side effects, including diarrhea, nausea, epigastric
iscomfort, and elevated liver enzyme levels. Gastrointesti-
al side effects are decreased by administration in divided
oses no greater than 100 mg (55,72).
The first study on the role of CoQ10 in HF was
ublished in 1976 (73). Serum and tissue levels of CoQ10
re lower in HF patients compared with normal control
ubjects (74,75). Additionally, the degree of CoQ10 defi-
iency may correlate with New York Heart Association
NYHA) functional class, left ventricular (LV) function,
nd mortality (76–79). This apparent deficiency of CoQ10
n HF has led to numerous trials seeking to establish the
fficacy of CoQ10 supplementation in varying etiologies of
F (Table 2). These trials are promising because they have
hown statistically significant improvement in a variety of
unctional, structural, and hemodynamic parameters, in-
luding ejection fraction (EF), stroke volume, cardiac out-
ut, pulmonary artery pressure, exercise capacity, and
uality of life (72,75,80–86). Additionally, decreases in
nd-diastolic volume, NYHA functional class, hospital
dmissions, dyspnea, and fatigue have also been docu-
ented. However, results have been mixed (87,88). The
argest trial conducted with CoQ10 in an HF population
as not a double-blind, placebo-controlled study (72).
onversely, several of the studies showing no effect have
een criticized for not achieving adequate CoQ10 serum
evels, in addition to being too short in duration (87–89).
eta-analyses to evaluate the overall findings of CoQ10
rials appear to support many of the aforementioned benefits
f CoQ10 in HF (90–92). In short, CoQ10 appears to be a
afe and potentially effective nutritional supplement for the
reatment of HF, based primarily, however, on small studies
nd meta-analyses. Larger trials of CoQ10 in combination
ith other micronutrients are needed to show a reduction in
orbidity and mortality for HF patients already receiving
tandard therapy.
-Carnitine
-carnitine is an amino acid derivative synthesized primarily
rom the amino acids lysine and methionine (93). It plays a
ritical role in fatty acid transport into the mitochondria
94). Additionally, L-carnitine reverses the inhibition of
yruvate dehydrogenase, allowing for improved coupling
etween glycolysis and glucose oxidation (95). Genetic
arnitine deficiency, secondary to a plasma membrane trans-
orter defect, results in a cardiomyopathy (28). Lastly, an
lternate form of the molecule, propionyl-L-carnitine, has a bigh penetration rate into myocytes, and its products can
erve as a substrate of the Krebs cycle (93). Propionyl-L-
arnitine has been shown to improve contractile function in
he isolated working rat heart (96) and also to reduce the
actate and hydrogen burden in the hypertrophied human
eart by increasing glucose oxidation (95).
L-carnitine is either supplied in the diet or produced
ndogenously, although daily consumption far exceeds en-
ogenous production (97). L-carnitine deficiency in the
ailing heart has been well documented (36,98–100). As
oted previously, infants have a reduced ability to biosyn-
hesize L-carnitine; whether the fetal gene program contrib-
tes to the deficiency of L-carnitine seen in HF is unknown.
tudies have also shown that plasma levels of L-carnitine
ften do not reflect the tissue level of L-carnitine because a
ignificant intracellular-to-extracellular gradient is main-
ained by sodium-dependent pumps (23,100). Most trials
onducted with L-carnitine supplements in HF have used
oses of 1.5 to 3 g/day, which seem to be well tolerated
101–105).
There have been several promising studies evaluating the
ole of L-carnitine in cardiac diseases, including HF (Table 3).
owever, their value has been limited by their design and
nconsistent results. Although multicenter trials, such as the
EDIM (L-Carnitine Ecocardiografia Digitalizzata Infarto
iocardico) study, have shown a benefit of L-carnitine on
ardiac remodeling after myocardial infarction (106), less is
nown about L-carnitine in the treatment of HF of non-
schemic causes. Supplementation of L-carnitine or its
nalog, propionyl-L-carnitine, in HF has led to statistically
ignificant increases in exercise capacity, maximum exercise
ime, peak heart rate, and peak oxygen consumption (101–
04). Small studies on hemodynamic and echocardiographic
ffects of supplementation also have shown promising re-
ults, reducing pulmonary artery pressure, as well as LV
ystolic, diastolic, left atrial, and end-diastolic dimensions
102). Improvements in EF have also been observed, albeit
ot consistently (102,104). Interpretation has been limited
ue to lack of control groups and high dropout rates in
ertain trials (102,103). A larger European study relied on
ubgroup analyses to observe an effect (101). One trial
evealed a potentially interesting benefit of L-carnitine on
ortality by demonstrating a significantly improved 3-year
urvival in patients with dilated cardiomyopathy and
YHA functional class III to IV HF (105). It is therefore
roposed that both carnitine and propionyl-L-carnitine
arrant further study in patients with HF.
hiamine (Vitamin B1) and Other B Vitamins
hiamine (vitamin B1) is a water-soluble B vitamin that
lays an important role as a coenzyme in carbohydrate
etabolism. Through the addition of magnesium and ATP,
hiamine is converted to thiamine pyrophosphate by the
nzyme thiamine pyrophosphokinase (107). As the meta-
olically active form of thiamine, thiamine pyrophosphate
Selected Trials With CoQ10 Supplementation in HFTable 2 Selected Trials With CoQ10 Supplementation in HF
Study Author
(Ref. #) Year
No. of
Patients Study Design Primary End Point
NYHA
Functional
Class Results Dose
Side Effects
Related to
CoQ10 Remarks
Baggio et al.
(72)
1994 2,664 Post-marketing
surveillance
study
Assessment of clinical signs and
symptoms using a 7-point scale
II–III Improvement of at least 3
symptoms seen in 54% of
patients
50–150 mg/day None Not a double-blind, placebo-controlled
study. Doses varied. Before modern
therapy was available. Used point
system for clinical improvement.
Langsjoen
et al. (75)
1985 19 Double-blind,
placebo
double-
crossover
Evaluation of EF, SV, CoQ10 serum
level, weight, and clinical status
over 28 weeks
III–IV 1 EF and SV,1 CoQ10 serum
level
33.3 mg BID None Small size and before modern therapy
Belardinelli
et al. (80)
2006 23 Double-blind,
placebo-
controlled
crossover
At 4 weeks effects of CoQ10 and
exercise training on VO2 max, EF,
and endothelium-dependent
dilation of brachial artery
II–III Increase in VO2 max, increase in
LVEF at rest and peak,
improvement in endothelium-
dependent dilation of brachial
artery
100 mg TID None Small study size. Also evaluated patients
in exercise training regimen.
Morisco et al.
(81)
1993 191 Double-blind
placebo-
controlled
Incidence of hospitalization and
life-threatening pulmonary
edema
III–IV 2 Hospitalization and pulmonary
edema
2 mg/kg/day NA Small size and before modern therapy
Munkholm
et al. (85)
1999 22 Double-blind,
placebo-
controlled
Right heart catheterization for RAP,
RVSP, EDP, PAP, and PCWP at
rest, 1, or 3 min of work done at
12 weeks
II–III 1 Stroke index at rest and work,
2 PAWP at rest.2 PCWP at
work. Otherwise no changes.
100 mg BID NA Small study size
Keogh et al.
(86)
2003 39 Double-blind,
placebo-
controlled
Physician-assessed NYHA symptom
functional class at 3 months
II–III Small but statistically significant
improvement in NYHA
functional class
150 mg/day NA Small study size. Treated with ACEI but
not beta-blockers.
Khatta et al.
(87)
2000 46 Double-blind,
placebo-
controlled
At 6 months change in EF, as
assessed by nuclear
ventriculography, and change in
peak O2 consumption
III–IV No effect on EF, peak O2
consumption
200 mg/day None Small study size, lower CoQ10 serum
levels attained
Watson et al.
(88)
1999 30 Double-blind,
placebo-
controlled
crossover
At 3 months evaluation of LVEDV,
LVESV, and EF. Right heart
catheterization for CO and
PCWP.
Not reported;
EF 35%
No significant change 33 mg TID None Small size, used lower dose of CoQ10
ACEI angiotensin-converting enzyme inhibitor; BID twice daily; CO cardiac output; EDP end-diastolic pressure; EF ejection fraction; LVEDV left ventricular end-diastolic volume; LVEF left ventricular ejection fraction; LVESV left ventricular end-systolic volume;
NYHA New York Heart Association; PAP pulmonary artery pressure; PAWP pulmonary artery wedge pressure; PCWP pulmonary capillary wedge pressure; RAP right atrial pressure; RVSP right ventricular systolic pressure; SV stroke volume; TID three times
daily; other abbreviations as in Table 1.
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Selected Trials With Carnitine in HFTable 3 Selected Trials With Carnitine in HF
Study Author
(Ref. #) Year
No. of
Patients Study Design Primary End Point
NYHA Functional
Class Results Dose
Side Effects
Related to
Carnitine Remarks
Study investigators
(101)
1999 353 Double-blind,
placebo-
controlled
At 6 months and evaluation of
exercise capacity using
bicycle exercise
II–III No difference in
maximum exercise
duration
1 g BID None No BB used (only ACEI and
diuretic), non-a priori
subgroup analysis.1
Max HR in patients with
higher EF (30%–40%).
Anand et al. (102) 1998 30 Single-blind,
placebo-
controlled
At days 1, 15, and 30
measurement of LV
function, hemodynamics,
hormone levels, exercise
capacity, and peak O2
consumption
II–III No change in LV function.
2 End-diastolic
dimensions and end
point septal separation.
2 PAP and PAWP on
days 1 and 30. No
change in hormone
levels.1 Peak O2
consumption, exercise
time, exercise HR.
Initial bolus 30 mg/kg,
then 500 mg TID
None Single blind and small
study size
Loster et al. (103) 1999 41 Double-blind,
placebo-
controlled
Bicycle ergometer test to
determine maximum
performance, systolic and
diastolic pressure, HR, and
ST changes at up to 180
days
II–III Improved performance.
Trend toward improved
hemodynamic
parameters.
1 g TID NA Small size and limited end
point assessments, high
dropout rate
Mancini et al. (104) 1992 60 Double-blind,
placebo-
controlled
LVEF and maximum exercise
time on ergometer bicycle
at up to 180 days
II–III 1 Maximum exercise
time and EF
500 mg TID NA Small size, before current
treatments available
Rizos (105) 2000 80 Double-blind,
placebo-
controlled
Measurement of LVEF,
maximum exercise time,
peak VO2 consumption,
arterial and pulmonary BP,
CO, and 3-year mortality
III–IV dilated
cardiomyopathy
1 3-yr survival.
Improved maximum
exercise time, peak O2
consumption, CO,
arterial/pulmonary BP
2 g/day GI discomfort in 3
patients (all
completed)
Limited to dilated
cardiomyopathy
Iliceto et al. (106) 1995 472 Double-blind,
placebo-
controlled
LV volume and EF at 12
months after MI
NA 2 LVEDV and LVESV. No
difference in LVEF.
9 g/day IV for 5 d,
then 6 g/day PO for
12 months
NA Evaluated results after
acute MI. Not in HF.
BB  beta-blocker; BP  blood pressure; EDV  end-diastolic volume; ESV  end-systolic volume; GI  gastrointestinal; HR  heart rate; IV  intravenous; LV  left ventricular; MI  myocardial infarction; PO  by mouth; other abbreviations as in Tables 1 and 2.
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Micronutrient Deficiencies: An Unmet Need in HF October 27, 2009:1660–73erves as a cofactor for the pyruvate dehydrogenase complex
nd for transketolase, both key mediators of energy substrate
etabolism. Thiamine deficiency results in decreased ATP
roduction and increased cellular acidosis on a metabolic
evel (108).
Thiamine itself is stored in the body in only small
mounts and cannot be produced endogenously (23). Ade-
uate nutritional intake through diet (whole grains, le-
umes, nuts) or supplements is therefore critical in prevent-
ng deficiency. Doses used in trials have ranged from 1.5 to
00 mg/day.
The cardiac effects of severe thiamine deficiency are
linically referred to as wet beriberi (109). A chronic disease
evelops consisting of a peripherally vasodilated state that
eads to fluid retention through activation of the renin-
ngiotensin system. The end result of thiamine deficiency is
igh-output HF (110). In the Western world, however, wet
eriberi is rarely encountered. Instead, concern focuses on
oderate thiamine deficiency in patients with HF. Animal
odels have shown that thiamine deficiency can lead to
ardiac dysfunction, hypertrophy, and arrhythmias without
he presence of beriberi (111–121). In patients with HF, the
ncidence of thiamine deficiency ranges from 13% to 93%
60–62,122–125). Patients with NYHA functional class
II/IV HF appear to have more severe deficiency than their
lass I/II counterparts (60). Furosemide, commonly used in
uch patients, may exacerbate this problem through urinary
xcretion of thiamine (60–63). There also appears to be an
ncreased need for thiamine in the setting of HF, as similar
utritional amounts are inadequate in HF patients com-
ared with controls (60).
Given the proposed role of thiamine deficiency in HF,
everal small studies have been conducted to examine the
linical utility of supplementation. Thiamine deficiency
ppears to respond to oral supplements as small as 1.5
g/day, as shown in 1 study of 100 hospitalized HF
atients (60). In one of the most promising trials, 30
atients with HF receiving furosemide were given either
hiamine (200 mg/day) or placebo (126). After only 1 week,
hiamine levels had increased, with statistically significant
mprovements in diuresis and EF noted. By the end of the
-week study, improvement in cardiac function was ob-
erved with a 22% increase in EF. Although results from
ther trials have been mixed (124,127), the known effects of
hiamine deficiency on the heart suggest that supplementa-
ion may be of therapeutic benefit if examined in larger HF
rials.
Riboflavin (vitamin B2) and pyridoxine (vitamin B6) play
ritical roles in carbohydrate energy metabolism and the
roduction of red blood cells. These B vitamins, like
hiamine, are water soluble, are subject to renal excretion,
ave limited tissue storage, and are dependent on intake.
herefore, their status may also be adversely affected by the
se of loop diuretics. Indeed, similar deficiencies in HF have
een reported (22). The prevalence of having a deficiency of sny one B vitamin in HF was recently reported to be 68%
35). Vitamin B12 and folate have also been shown to be
eficient in a small subset of HF patients (128). Although
hese vitamins have been postulated to play a role in
ndothelial dysfunction through homocysteine action, stud-
es to support an effect in HF are currently lacking.
mino Acids
mino acids play a dual role in cardiac metabolism. First,
hey are the “building blocks” of proteins. Second, they are
ntermediary metabolites in energy substrate metabolism
16,33). A relevant role is played by taurine, which com-
rises 25% of the cardiomyocyte amino acid pool in hu-
ans. Taurine is not a substrate for protein synthesis or
ntermediary metabolism, but rather functions both as an
ntioxidant and as an important endogenous regulator of
ntracellular calcium homeostasis (129–132). Taurine mod-
lates voltage-dependent calcium channels, sodium-calcium
xchange, and sodium-taurine cotransport. The net effect is
o protect heart muscle cells from calcium overload, on the
ne hand, and low calcium states on the other. Since
yocyte calcium levels increase in HF and contribute to
ellular injury, maintenance of appropriate taurine levels
ould seem to be critical. Taurine, like CoQ10, is also a
otent antioxidant and reacts with a variety of potentially
oxic intracellular aldehydes (133). Cytokine activity, par-
icularly TNF-alpha, is increased in HF; TNF-alpha has
een shown to decrease taurine levels (134). Lastly, the
dverse actions of angiotensin II are potentiated in taurine-
eficient cardiomyocytes (135).
Although taurine can be synthesized from methionine or
ysteine, and as such is not an essential amino acid, the
ajority is obtained from dietary sources such as fish and
ilk (136,137). The heart extracts its supply through active
ransport by a taurine transporter (138). In infants and the
lderly, taurine biosynthesis is reduced; thus, there was an
ncreasing dependence on dietary sources (137). It is an
ssential ingredient in infant formulas, as taurine deficiency
an produce HF. Taurine, dosed at up to 1 g 3 times per
ay, appears to be well tolerated (137). Indeed, large doses
f taurine are a central component of many popular caffeine
nergy drinks.
Taurine levels are reduced in ischemic cardiomyopathy
137,139,140). Animal studies have shown that supplemen-
al amino acids, including taurine, are beneficial in several
ardiac injury and HF models (24,25,30,141,142). In hu-
ans with HF, amino acid mixtures have resulted in
mprovements in exercise capacity (143–145). There is only
small study examining taurine supplementation specifi-
ally (129). After 6 weeks, a significant improvement in EF
as observed in the taurine-treated group. Additional stud-
es are needed to confirm any beneficial effects of amino acid
upplementation in HF.
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here are many other micronutrients of potential interest
ith respect to HF. Although the evidence surrounding
hem is not as robust as for the molecules we have
entioned above, and some may not play a role in energy
etabolism, it is worthwhile to briefly mention them to
rovide a complete picture of the field.
Creatine is a key regulator of energy metabolism in all
uscle tissues of the body, including the heart. Mitochon-
rial energy stored in the phosphate bond of ATP is
ransferred to phosphocreatine by creatine kinase (146). In
he failing myocardium, there is evidence that this system
ecomes dysfunctional and that the level of deficiency may
orrelate with the severity of HF (147–150). There are few
tudies specifically examining creatine supplementation in
F, however, and analysis is complicated by its effects on
keletal muscle and the alterations in creatinine levels that
ccur with supplementation that confuse monitoring of
enal function (151–153).
Vitamin D is a molecule that plays an important role in
he homeostasis of calcium, a key player in cardiac contrac-
ility. It is also an inhibitor of renin production (154). Low
itamin D levels have been observed in HF patients (155).
arly experiments have suggested that low vitamin D levels
ay contribute to cardiac dysfunction through both
alcium-dependent and calcium-independent processes
156,157).
Multiple cations, such as magnesium, potassium, zinc,
nd selenium, have been associated with HF to varying
egrees (158). Magnesium and potassium deficiencies have
een primarily related to arrhythmias in HF, although the
rognostic significance of this finding is unclear (159–161).
inc is an antioxidant that has been found to be deficient in
F patients, although the exact importance of this finding
emains unclear (162). Finally, selenium is a component of
lutathione peroxidase, an antioxidant enzyme that protects
gainst endothelial dysfunction (163). Dietary deficiency in
hina has been associated with a cardiomyopathy in chil-
ren, and there are case reports suggesting a role of severe
elenium deficiency in the development of HF after bariatric
urgery in the U.S. (164).
ultiple-Micronutrient Supplementation
limitation of many of the clinical trials reviewed here has
een the use of only a single supplement. Although this
llows researchers to focus on the effects of each micronu-
rient individually, it may potentially lead to minimal
linical outcomes if it simply shifts rate-limiting steps from
ne to another component of the complex energy-providing
athways. Correcting 1 deficiency thus, in theory, would
nmask 1 of the many other deficiencies present. Also, the
eed for a given nutrient may not be apparent, as blood
evels do not always reflect a deficiency or increased require-
ents in the diseased myocardium (e.g., L-carnitine). Aherefore, given the multiple-nutrient deficits in HF pa-
ients, an alternative strategy is to use a combination of
upplements to attempt to maximize clinical effects, as
erformed in animal experiments (27,36,165).
One study showed that cardiomyopathic hamsters had
eficiencies in CoQ10, L-carnitine, and taurine at the
yocardial level during the late stages of their disease (27).
upplementation for 3 months versus a placebo diet im-
roved the actual structure of myocyte sarcomeres and
itochondria, contractility, and cardiac function. In a more
ecent study, rats pre-treated with this combination before
oronary artery ligation exhibited markedly improved sur-
ival, cardiac function, and reduced infarct size when
ompared with placebo (165).
Few studies have included multiple-nutrient supplemen-
ation in human HF (Table 4). One study (79) examined
he effects of a nutrient drink. Although this supplement
ontains many nutrients, the ones relevant to this review
nclude CoQ10, carnitine, thiamine, and taurine. Forty-one
atients with ischemic cardiomyopathy (EF 40%) sched-
led for elective bypass surgery were randomized to either
he nutrient supplement or a similar-tasting placebo. The
roups were relatively well matched except for a slightly
igher age and lower digoxin use in the control group. The
atients were then followed for 40 to 45 days until their
urgery, at which point LV biopsies were obtained. These
issue samples were used to confirm the primary end points:
ncreases in myocardial levels of taurine, carnitine, and
oQ10. Indeed, tissue samples revealed 40% to 144%
igher levels of each of these nutrients in the treated group.
econdary end point analysis showed a decrease in left
entricular end-diastolic volume (LVEDV) when compared
ith placebo and a trend toward reduced left ventricular
nd-systolic volume (LVESV). However, EF was unaf-
ected. Adverse effects of the supplement were minimal.
he primary complaint was gastrointestinal, possibly due to
he large undivided dose of CoQ10 administered. An
solated increase in creatinine, not blood urea nitrogen, was
elt to likely be secondary to the breakdown of creatine
onsumed through the supplement. Overall, whereas the
esults were promising, the study did face several limita-
ions. The small sample size and short duration of the trial
ade detecting significant differences more difficult. Addi-
ionally, many patients in the study did not have clinical
ymptoms of HF at the onset of the trial. Thus, no
omment could be made on symptom improvement with
upplementation. The confirmation, however, of increased
evels of certain key nutrients in the myocardium with oral
dministration did reaffirm the validity of such a delivery
ethod for future trials.
Another study evaluating the role of multiple-
icronutrient supplementation in elderly HF patients has
lso showed promising results (166). In this trial, patients
ith stable, ischemic HF (EF 35%) were randomized to
ither capsules containing multiple nutrients or placebo.
lthough many vitamins and minerals were administered,
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Micronutrient Deficiencies: An Unmet Need in HF October 27, 2009:1660–73he substances relevant to this review were CoQ10 and
hiamine. No significant adverse effects were noted during
he study. Patients were followed for 9 months, at which
oint the primary end point, a change in EF, was evaluated
y cardiac magnetic resonance imaging (MRI). The active
ompound, but not placebo, significantly improved EF,
ith a significant decrease in LVESV and LVEDV. There
as an improvement in quality-of-life scores at 6 months,
eaffirming the need for long-term observation to witness
mprovement from supplementation. However, there were
o changes in NYHA functional class or exercise capacity,
hich the authors attributed to the small sample size.
verall, this study did show improvement in cardiac func-
ion parameters on MRI, which is highly promising. Yet
gain, a larger study population would have been helpful for
etecting more subtle differences, as noted by the authors.
lso, the inclusion of key missing nutrients, such as carni-
ine and amino acids, would have minimized the chance of
nmasking these deficiencies when administering a more
imited supplement cocktail.
Both of the trials described here, in their own way,
llustrate the promise for long-term improvement of cardiac
unction in HF patients when key nutrients are adminis-
ered simultaneously. Future studies are needed to first
onfirm these results and to then lead to a better definition
f the ideal regimen to maximize cardiac benefits.
utlook and Challenges
he optimal treatment of HF remains a formidable chal-
enge, as suggested by the disappointing outcomes of recent
rials (10,59,167–169). There is a clear need for new
herapies that can work synergistically with standard treat-
ents to reverse the progression of the disease. This calls for
more detailed examination of the role of nutrition in the
reatment of HF. The recent GISSI-HF (Gruppo Italiano
er lo Studio della Sopravvivenza nell’Infarto Miocardio–
eart Failure) trial, for example, has shown the promise of
uch a complementary approach with respect to fatty acids
170).
In the failing heart, the presence of viable, but dysfunc-
ional, myocardium is relatively common and is an impor-
ant predictor of improvement of systolic function (reverse
emodeling) in response to medical and revascularization
herapies (171–174). Certain causes of dysfunctional myo-
ardium are known, such as stunning hibernation due to
hronic ischemia (175). Perturbed energetics due to micro-
utrient deficiencies may also be responsible for dysfunc-
ional myocardium. The chronic improvement or normal-
zation of contractility of dysfunctional myocardium may be
sed as a surrogate end point to assess the effects of
icronutrients in HF (171,173,174,176).
An underexplored therapeutic field involves micronutri-
nts and their effects on the energy dynamics of the heart.
he nutritional studies summarized here show interestingresults in the treatment of HF. It is well known that theSe
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October 27, 2009:1660–73 Micronutrient Deficiencies: An Unmet Need in HFeart has unique and significant energy requirements due to
ts mechanical pumping function and that a failing heart is
n a perpetual state of increased stress due to neurohormonal
ctivation. Defects in complex pathways, such as those
nvolved in ATP production and driving calcium cycling,
esult in further energy imbalances and lead to additional
ontractile impairment in HF. Results from animal models
nd small human trials suggest a potential cardiac benefit to
orrecting micronutrient deficiencies. To varying degrees,
oQ10, L-carnitine, thiamine, taurine, and amino acids
ave all been shown to improve functional, structural, and
emodynamic parameters in HF patients, mostly by im-
roving flux through the cycles of energy transfer in the
eart (Fig. 1). Micronutrients have been shown to improve
F (90,91,104,126,129). However, there are substantial
imitations to the research in its current state. First, studies
ave often been small, with inconsistent end points, and
hort in duration. A few trials were not randomized, and
ost did not examine key end points such as improvement
n pump function and clinical outcomes. Lastly, the focus on
eplenishment of only a single nutrient has possibly masked
herapeutic effects by simply shifting rate-limiting steps to
ther energy pathways. Given the complex nature of myo-
ardial energy metabolism (19), it is not likely that a single
ubstance alone will be able to reverse the widespread
eficits present in HF, similar to a starving individual
equiring diverse nutrition from multiple food groups for
urvival. These design limitations have together contributed
o the often inconsistent results evident in the existing
iterature (Table 5). Animal and human studies that have
ttempted to overcome the single-nutrient restriction have
ielded interesting, but not conclusive, results (79,166).
urrent advances in imaging technology (e.g., MRI, echo-
ardiography) have also not yet been adequately utilized in
his field (171). No single trial conducted to date has met
he necessary criteria to demonstrate a significant clinical
enefit when 1 or more micronutrients were added to
tandard therapy for HF (Table 5). Such a study should
how conclusive improvement in important outcomes such
s hospitalizations and mortality in HF when micronutri-
nts are added to standard therapy. Compared with the
andmark multicenter trials of existing HF therapies, the
tudies of nutritional supplementation are in a relative state
imitations of Existing Trials and Suggested Improvements in MethTable 5 Limitations of Existing Trials and Suggested Improvem
Pitfalls in Previous Study Methodologies
Supplementation of only a single nutrient
Small sample size (largest multinutrient trial has 41 patients)
No pre-trial assessment of viable, but dysfunctional, myocardium
Conducted prior to the use of current standard-of-care therapy for HF
Short duration of study
Evaluation of limited end points
RI  magnetic resonance imaging; other abbreviations as in Tables 1, 2, and 3.f infancy (177–179). If proven to be beneficial, the wide-pread availability of these individual nutritional compounds
rom generic manufacturers may offer patients a lower-cost
herapy not burdened by development and marketing expenses.
In summary, the potential importance of any novel
herapy in a disease with increasing prevalence, such as HF,
ecessitates a timely and detailed examination of efficacy in
clinical trial population. The unmet energy requirements
f the failing heart have been carefully detailed, and the
olecules controlling energy and substrate utilization are
qually recognized from extensive laboratory work. Unfor-
unately, the effort dedicated up to now to testing the
heoretical benefits of these micronutrients in a scientifically
igorous clinical trial fashion has been insufficient to yield
ny conclusions that can be applied to widespread practice.
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